title: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.
abstract: OBJECTIVE
  To review the literature on the association between antidiabetic agents and morbidity and mortality in people with heart failure and diabetes.
  
  
  METHODS
  Systematic review and meta-analysis of controlled studies (randomised trials or cohort studies) evaluating antidiabetic agents and outcomes (death and admission to hospital) in patients with heart failure and diabetes.
  
  
  METHODS
  Electronic databases, manual reference search, and contact with investigators.
  
  
  METHODS
  Two reviewers independently extracted data. Risk estimates for specific treatments were abstracted and pooled estimates derived by meta-analysis where appropriate.
  
  
  RESULTS
  Eight studies were included. Three of four studies found that insulin use was associated with increased risk for all cause mortality (odds ratio 1.25, 95% confidence interval 1.03 to 1.51; 3.42, 1.40 to 8.37 in studies that did not adjust for diet and antidiabetic drugs; hazard ratio 1.66, 1.20 to 2.31; 0.96, 0.88 to 1.05 in the studies that did). Metformin was associated with significantly reduced all cause mortality in two studies (hazard ratio 0.86, 0.78 to 0.97) compared with other antidiabetic drugs and insulin; 0.70, 0.54 to 0.91 compared with sulfonylureas); a similar trend was seen in a third. Metformin was not associated with increased hospital admission for any cause or for heart failure specifically. In four studies, use of thiazolidinediones was associated with reduced all cause mortality (pooled odds ratio 0.83, 0.71 to 0.97, I2=52%, P=0.02). Thiazolidinediones were associated with increased risk of hospital admission for heart failure (pooled odds ratio 1.13 (1.04 to 1.22), I2=0%, P=0.004). The two studies of sulfonylureas had conflicting results, probably because of differences in comparator treatments. Important limitations were noted in all studies.
  
  
  CONCLUSIONS
  Metformin was the only antidiabetic agent not associated with harm in patients with heart failure and diabetes. It was associated with reduced all cause mortality in two of the three studies.
authors.affiliation: Institute of Health Economics, Edmonton, AB, Canada, T5J 3N4.
authors.forename: Dean T
authors.initials: DT
authors.lastname: Eurich
authors.forename: Finlay A
authors.initials: FA
authors.lastname: McAlister
authors.forename: David F
authors.initials: DF
authors.lastname: Blackburn
authors.forename: Sumit R
authors.initials: SR
authors.lastname: Majumdar
authors.forename: Ross T
authors.initials: RT
authors.lastname: Tsuyuki
authors.forename: Janice
authors.initials: J
authors.lastname: Varney
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Johnson
mesh_terms: D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000401:mortality*; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D007004:Hypoglycemic Agents